Back to News
Market Impact: 0.28

2 Top Stocks That Could Double in 2026

CPNGOSCRAMZNNFLXNVDA
Company FundamentalsCorporate EarningsCorporate Guidance & OutlookTechnology & InnovationConsumer Demand & RetailHealthcare & BiotechRegulation & LegislationCybersecurity & Data Privacy
2 Top Stocks That Could Double in 2026

Coupang (market cap ~$42B) generated roughly $34B in trailing revenue and reported an adjusted earnings margin of 8.8% last quarter while growing revenue ~20% year-over-year; short-term investments (Taiwan expansion, food/fashion/fintech services, AI chip and potential cloud infrastructure) have depressed consolidated margins but could drive margin expansion and share-price upside in 2026 despite a recent data breach. Oscar Health serves ~2 million members, produced $11.3B in trailing revenue, has materially raised 2026 premiums to offset rising claims and faces the expiration of ACA subsidies on Jan. 1; management targets ~5% operating margins (roughly $500M) next year, and with a market value near $4B the stock is presented as deeply undervalued if margins and pricing normalize.

Analysis

Market structure: Coupang (CPNG) and Oscar Health (OSCR) are beneficiaries of platform scale and pricing power shifts—Coupang via vertically integrated logistics and potential cloud/AI stack sales, Oscar via aggressive premium resets. Winners include AI chip/cloud suppliers and tech-enabled insurers; losers are legacy retailers and subsidy-dependent insurers if ACA tax credits lapse. Expect stronger pricing power in 2026 for both if execution holds; logistics capacity constraints and labor/fuel costs are the main supply-side limits. Risk assessment: Tail risks are material — a large regulatory fine or erosion of consumer trust from Coupang’s data breach, and a permanent loss of ACA subsidies for Oscar that triggers >10% membership decline and adverse selection. Immediate (days) risk centers on political/legislative headlines (Jan 1, 2026 subsidy cliff), short-term (weeks–months) on premium filing outcomes and Q4 results, long-term (2026+) on margin recovery and capital intensity of AI/cloud projects. Trade implications: Favor selective exposure: convex, event-driven positions (LEAPs or call spreads) into 2026 margin expansion for CPNG and conditional long in OSCR if subsidy outcome is neutral/positive. Use put protection around Jan 2026 for OSCR; consider pair trades to isolate execution risk (long CPNG / short larger-cap US retail). Rebalance after two concrete catalysts: (1) Q4-2025 consolidated margin print for CPNG and (2) post-Jan-1 subsidy membership readouts for OSCR. Contrarian angles: Consensus underprices execution and policy risk — market assumes clean 2026 rebound; that may be overdone for Oscar if adverse selection accelerates claims. Conversely, Coupang’s investments (AI chips, cloud) could be capital drains that delay margin recovery — if consolidated margin doesn’t expand by H1 2026, downside is underfollowed. Historical parallel: Amazon’s high-investment phase before margin inflection; outcomes diverge based on capital efficiency and regulation.